Qube Research & Technologies (QRT)
RLMD icon

Qube Research & Technologies (QRT)’s Relmada Therapeutics RLMD Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.79M Buy
691,545
+38,212
+6% +$267K ﹤0.01% 1651
2026
Q1 		$4.55M Buy
653,333
+497,804
+320% +$2.36M 0.01% 1713
2025
Q4 		$751K Buy
+155,529
New +$521K ﹤0.01% 2667
2024
Q3 		– Sell
-56
Closed -$168 – 3976
2024
Q2 		$168 Sell
56
-72,923
-100% -$264K ﹤0.01% 3405
2024
Q1 		$339K Buy
72,979
+68,005
+1,367% +$328K ﹤0.01% 2748
2023
Q4 		$20.6K Buy
4,974
+1,136
+30% +$3.36K ﹤0.01% 3480
2023
Q3 		$11.5K Sell
3,838
-41,691
-92% -$124K ﹤0.01% 3292
2023
Q2 		$112K Buy
+45,529
New +$126K ﹤0.01% 1929

Other funds holding RLMD

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Qube Research & Technologies (QRT)'s RLMD Position: Q2 2026 in Review

Qube Research & Technologies (QRT) increased its Relmada Therapeutics (RLMD) stake by 5.8% in Q2 2026, buying an estimated $267K and bringing the position to 691,545 shares worth $4.79M. The position accounts for ﹤0.01% of the portfolio, ranked #1651.

Qube Research & Technologies (QRT) first reported a position in RLMD in Q2 2023 and has held it in 8 quarters since. 126 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.

  • Qube Research & Technologies (QRT) held 691,545 shares of Relmada Therapeutics worth $4.79M as of Q2 2026.
  • Qube Research & Technologies (QRT) bought 38,212 Relmada Therapeutics shares in Q2 2026, an estimated $267K.
  • Relmada Therapeutics made up ﹤0.01% of Qube Research & Technologies (QRT)'s portfolio in Q2 2026, its #1651 holding.
  • Qube Research & Technologies (QRT) first reported a position in Relmada Therapeutics in Q2 2023 and has held it in 8 quarters since.
  • 126 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q2 2026, filed 14 Aug 2026.